Journal
BLOOD
Volume 132, Issue 7, Pages 689-693Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-03-834440
Keywords
-
Categories
Funding
- Amgen, Inc
- Global Blood Therapeutics, Inc.
Ask authors/readers for more resources
In 2017, the Food and Drug Administration approved 2 medications for sickle cell anemia (SCA): hydroxyurea for children and L-glutamine for children and adults. The approval of hydroxyurea was long overdue, but the approval of L-glutamine was a surprise to many. Any effective new treatment for SCA is a welcome advance, but there are few published studies of L-glutamine as a specific treatment for SCA. Accordingly, there are many unanswered questions about its efficacy, safety, and role in current therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available